Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 1973-1979

  Li, Li ^a   Wang, Limei ^b   Zhang, Wei ^a   Tang, Bujian ^a   Zhang, Jieqing ^a   Song, Honglin ^a   Yao, Desheng ^a   Tang, Yong ^a   Chen, Xinqiu ^a   Yang, Zhihua ^c   Wang, Gangduo ^d   Li, Xiping ^d   Zhao, Jinshun ^d   Ding, Hong ^d   Reed, Eddie ^d   Li, Qingdi Q ^d,e  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c CANCER HOSPITAL   (China)

^d WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Ovarian cancer; VEGF

Indexed keywords

VASCULOTROPIN;

ARTICLE; ASCITES; BLOOD DONOR; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; OVARY METASTASIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TUMOR GROWTH;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3242658330     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Brekken RA and Thorpe PE: Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 21: 4221-4229, 2001.
2. Garzetti GG, Ciavattini A and Lucarini G: Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining. Gynecol Oncol 73: 396-401, 1999.
3. Santin AD, Hermonat PL and Parham GP: Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstet Gynecol 94: 78-82, 1999.
4. Fujimoto J, Sakaguchi H and Tamaya T: Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer 80: 827-833, 1999.
5. Shen GH, Ghazizadel M, Kawanami O, Shimizu H, Jin E, Araki T and Sugisaki Y: Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83: 196-203, 2000.
6. Abulafia O, Triest WE and Sherer DM: Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 72: 220-231, 1999.
7. Junker K: Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer 33 (Suppl 1): S17-S24, 2001.
8. Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5 (Suppl 1): S37-S44, 2000.
9. Chung YS, Maeda K and Sowa M: Prognostic value of angiogenesis in gastrointestinal tumours. Eur J Cancer 32A: 2501-2505, 1996.
10. Tomisawa M, Tokunaga T and Nakamura M: Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 35: 133-137, 1999.
11. Boocock CA, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR and Smith SK: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87: 506-516, 1995.
12. Tian X, Song S, Wu J, Meng L, Dong Z and Shou C: Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGCS03. Biochem Biophys Res Commun 286: 505-512, 2001.
13. Liu B, Earl HM and Seymour LW: Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun 217: 721-727, 1995.
14. Langer I, Vertongen P and Robberecht P: Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol 34: 386-393, 2000.
15. Herold-Mende C, Steiner HH and Mueller MM: Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. Lab Invest 79: 1573-1582, 1999.
16. Masood R, Cai J and Gill PS: Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98: 1904-1913, 2001.
17. Dias S, Zhu Z, Wu Y and Rafii S: Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 106: 511-521, 2000.
18. Greenlee RT, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
19. Ogawa S, Kaku T and Nakano H: Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 176: 111-118, 2002.
20. Brustmann H and Naude S: Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol 84: 47-52, 2002.
21. Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S and Parham GP: Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 20: 177-181, 1999.
22. Paley PJ, Staskus KA, Carson LF and Ramakrishnan S: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80: 98-106, 1997.
23. Boss EA, Massuger LF and Sweep CG: Vascular endothelial growth factor in ovarian cyst fluid. Cancer 91: 371-377, 2001.
24. Mesiano S, Ferrara N and Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153: 1249-1256, 1998.
25. Chen CA, Cheng WF, Lee CN, Chen TM, Kung CC, Hsieh FJ and Hsieh CY: Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol 74: 235-240, 1999.
26. Hartenbach EM, Olson TA, Goswitz JJ, Carson LF and Ramakrishnan S: Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 121: 169-175, 1997.
27. Young RC, Decker DG and Wharton JT: Staging laparotomy in early ovarian cancer. JAMA 250: 3072-3076, 1983.
28. Plaxe SC, Deligdisch L and Dottino PR: Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol Oncol 38: 367-372, 1990.
29. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S and Tamaya T: Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 83: 2528-2533, 1998.
30. Fujimoto J, Sakaguchi H and Aoki I: Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer 85: 313-316, 2001.
31. Paley PJ, Goff BA and Gown AM: Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 78: 336-341, 2000.
32. Oehler MK and Caffier H: Diagnostic value of serum VEGF in women with ovarian tumors. Anticancer Res 19: 2519-2522, 1999.
33. Duyndam MC, Hilhorst MC and Schluper HM: Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 160: 537-548, 2002.
34. Kraft A, Weindel K and Ochs A: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85: 178-187, 1999.
35. Oehler MK and Caffier H: Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res 20: 5109-5112, 2000.